Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Human Epidermal Growth Factor 2 Low Breast Cancer”

18 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 18 of 18 results

Testing effectiveness (Phase 2)Study completedNCT06188559
What this trial is testing

BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Eisai Inc. 56
Early research (Phase 1)Looking for participantsNCT07137416
What this trial is testing

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Invasive Breast Carcinoma+13 more
National Cancer Institute (NCI) 36
Testing effectiveness (Phase 2)Study completedNCT03321981
What this trial is testing

MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.

Who this might be right for
Breast Cancer Metastatic
Merus B.V. 105
Testing effectiveness (Phase 2)Looking for participantsNCT07498478
What this trial is testing

Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment

Who this might be right for
Breast Cancer
TransThera Sciences (Nanjing), Inc. 94
Not applicableLooking for participantsNCT05573893
What this trial is testing

PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan

Who this might be right for
Breast NeoplasmsBreast CancerNeoplasm Metastasis
AstraZeneca 800
Not applicableStudy completedNCT04807595
What this trial is testing

Estimation of the Prevalence of HER2 Low and Describe the SoC, Treatment Patterns, and Outcome in Real-world Practice Among Unresectable and/or Metastatic Breast Cancer Patients With HER2 Low Status

Who this might be right for
Breast Cancer
AstraZeneca 798
Early research (Phase 1)Study completedNCT04147819
What this trial is testing

A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein

Who this might be right for
Cancers With HER2 Expression
Bayer 14
Testing effectiveness (Phase 2)Looking for participantsNCT06263543
What this trial is testing

Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC

Who this might be right for
Breast CancerMetastatic Breast CancerAdvanced Breast Cancer+2 more
Reshma L. Mahtani, D.O. 75
Large-scale testing (Phase 3)Looking for participantsNCT06966700
What this trial is testing

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Who this might be right for
Breast NeoplasmsTriple Negative Breast NeoplasmsHR Low-Positive/HER2-Negative Breast Neoplasms
Merck Sharp & Dohme LLC 2,400
Large-scale testing (Phase 3)Active Not RecruitingNCT05840211
What this trial is testing

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

Who this might be right for
Locally Advanced or Unresectable Metastatic Breast CancerStage IV Breast Cancer
Gilead Sciences 654
Testing effectiveness (Phase 2)Looking for participantsNCT06330064
What this trial is testing

Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

Who this might be right for
Recurrent or Metastatic Solid Tumors
Daiichi Sankyo 680
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07757230
What this trial is testing

A Phase II Study of SSGJ-612 Plus a HER2-Targeted ADC in HR-Positive, HER2-Low or HER2-Ultralow Expression Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Shenyang Sunshine Pharmaceutical Co., LTD. 87
Testing effectiveness (Phase 2)Looking for participantsNCT06797635
What this trial is testing

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

Who this might be right for
Breast NeoplasmsBreast Cancer
Merck Sharp & Dohme LLC 372
Large-scale testing (Phase 3)Active Not RecruitingNCT06018337
What this trial is testing

DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

Who this might be right for
Metastatic Breast Cancer
DualityBio Inc. 541
Testing effectiveness (Phase 2)UnknownNCT05953168
What this trial is testing

T-DXd in the First-Line Treatment of Locally Advanced or Metastatic TNBC-LAR HER2-low Patients

Who this might be right for
Triple-Negative Breast Cancer
Fudan University 69
Not applicableStudy completedNCT05913440
What this trial is testing

HER2-low Unresectable and/or Metastatic Breast Cancer in Russia

Who this might be right for
Breast Cancer
AstraZeneca 1,669
Large-scale testing (Phase 3)Active Not RecruitingNCT03734029
What this trial is testing

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

Who this might be right for
Breast Cancer
Daiichi Sankyo 557
Testing effectiveness (Phase 2)Looking for participantsNCT07796880
What this trial is testing

Neoadjuvant Culmerciclib Combined With Endocrine Therapy for Hormone Receptor-Positive， Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer

Who this might be right for
Hormone Receptor-Positive Breast CancerHER2 Low Breast CarcinomaEarly-Stage Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 80